Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Current cancer immunotherapies, like checkpoint inhibitors and CAR T cells, rely on alpha beta T (αβT) cells recognizing tumor neoantigens, limiting efficacy in tumors with low mutational burden.
• Chimeric antigen receptor T (CAR T) cell therapy faces challenges in solid tumors due to a scarcity of suitable targets.
• This has led to a resurgence of interest in gamma delta T (γδT) cells for cancer treatment.

Purpose of the Study:

• To review the challenges and opportunities in the clinical application of γδT cell-based cancer immunotherapies.
• To highlight the potential of γδT cells as a therapeutic strategy for a broad range of cancers.

Main Methods:

• Review of existing literature on γδT cell biology and cancer immunotherapy.
• Analysis of the mechanisms underlying γδT cell cytotoxicity and tumor recognition.
• Discussion of clinical implementation strategies for γδT cell therapies.

Main Results:

• γδT cells exhibit potent cytotoxicity against diverse hematological and solid tumors, often independent of tumor-associated antigens.
• γδT cell therapy has the potential to preserve normal tissues.
• The precise mechanisms of tumor-specific γδT cell activity and self-recognition require further elucidation.

Conclusions:

• γδT cells represent a promising avenue for cancer immunotherapy, offering broader applicability than current αβT cell-based approaches.
• Overcoming the current knowledge gaps in γδT cell mechanisms is essential for successful clinical translation.
• Further research and development are needed to fully harness the therapeutic potential of γδT cells and their receptors.